All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

The combination of cabozantinib and atezolizumab elicited responses in patients with non–clear cell renal cell carcinoma, according to extended follow-up data from the phase 1b COSMIC-021 trial.

FDA Panel Votes in Support of Favorable Benefit-Risk Profile for Polatuzumab Vedotin in Previously Untreated LBCL

March 9th 2023

The FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 that data from the phase 3 POLARIX trial support a favorable benefit-risk profile for polatuzumab vedotin-piiq in patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified.

Minimally Invasive Surgery, PARP Inhibitors, ADCs Propel Treatment Advances Across Gynecologic Oncology

March 9th 2023

Jubilee Brown, MD, discusses future considerations for using minimally invasive surgery and PARP inhibitors in ovarian cancer, how immunotherapies have fulfilled an unmet need in cervical cancer, and the importance of leveraging molecular profiling to determine personalized therapeutic strategies in endometrial cancer.

Durvalumab-Based Treatment Before and After Surgery Improves EFS in Early-Stage NSCLC

March 9th 2023

Durvalumab plus neoadjuvant chemotherapy followed by surgery and adjuvant single-agent durvalumab significantly improved event-free survival vs neoadjuvant chemotherapy and surgery alone in patients with resectable stage IIA-IIIB non–small cell lung cancer.

COVID-19 Vaccine Efficacy Decreases With Ruxolitinib Use in MPNs

March 9th 2023

Treatment with ruxolitinib impaired antibody responses to complete vaccination with the BNT162b2 SARS-CoV-2 vaccine in patients with myelofibrosis or polycythemia vera.

Study Shows Women Over Age 65 With Low-risk Breast Cancer Could Skip Postoperative Radiation Therapy

March 9th 2023

A recently published study in the New England Journal of Medicine provides further data to support that certain female patients over age 65 can achieve positive outcomes without postoperative radiation.

Adjuvant Osimertinib Elicits OS Improvement in Early-Stage EGFR-Mutated NSCLC

March 9th 2023

Osimertinib produced a statistically significant and clinically meaningful improvement in overall survival compared with placebo as adjuvant treatment for patients with stage IB, II, or IIIA, EGFR-mutated non–small cell lung cancer after complete tumor resection with curative intent.

STELLAR-303 Aims to Carve Out Space for XL092 in mCRC Treatment Paradigm

March 9th 2023

Despite incremental advances in the treatment landscape of metastatic colorectal cancer, patients with the disease still face a poor prognosis.

PFS Benefit With Frontline Nivolumab/Cabozantinib Vs Sunitinib Is Independent of PD-L1 or c-MET Status in Advanced RCC

March 9th 2023

The progression-free survival benefit associated with the combination of nivolumab plus cabozantinib compared with sunitinib was largely independent of PD-L1 and c-MET status in previously untreated patients with advanced or metastatic renal cell carcinoma.

FDA Grants Fast Track Designation to IK-175 in Combination With Nivolumab in Urothelial Carcinoma

March 8th 2023

The FDA has granted a fast track designation to the novel aryl hydrocarbon receptor antagonist IK-175 in combination with nivolumab for the treatment of patients with advanced urothelial carcinoma who have progressed on or within 3 months of receiving the last dose of checkpoint inhibitors.

Increased Germline Testing Rates Promote Crucial Breast Cancer Care

March 8th 2023

Susan M. Domchek, MD, highlights key points related to her presentation on germline testing and breast cancer treatment.

Post-Hoc Analysis Provides Quantitative Evidence on Efficacy of Frontline mCRPC Treatments After Progression on Apalutamide

March 8th 2023

Boris A. Hadaschik, MD, discusses results from a post-hoc analysis of subsequent therapy for patients with nonmetastatic castration-resistant prostate cancer who progressed following treatment with apalutamide.

Ruxolitinib Demonstrates 6-Month Hematocrit Reduction in Polycythemia Vera

March 8th 2023

Treatment with ruxolitinib significantly reduced hematocrit levels and the number of yearly phlebotomies in patients with polycythemia vera, according to findings from a prespecified futility analysis of the phase 2b RuxoBEAT trial.

Making Pancreatic Cancer Treatments More Effective

March 8th 2023

Pancreatic cancer diagnoses are increasing more rapidly than any other cancer type while remaining one of the most deadly cancers.

FDA Accepts BLA Resubmission for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

March 8th 2023

The FDA’s Office of Therapeutic Products has accepted a resubmission of the biologics license application (BLA) for remestemcel-L for the treatment of pediatric patients with steroid-refractory, acute graft-vs-host-disease.

BET Inhibitors in Cancer Therapy: Finding the Right Combination

March 8th 2023

An understanding of BET protein dysregulation, which leads to abnormal expression of oncogenes, has prompted investigators to explore the idea of these proteins as a therapeutic target for cancer.

Updated MAGNITUDE Data Support Niraparib Combination in mCRPC and HRR Gene Alterations

March 8th 2023

Eleni Efstathiou, MD, PhD, expands on the updated interim data from the MAGNITUDE trial and sheds light on the utility of PARP inhibitor combinatorial strategies in patients with mCRPC and HRR gene alterations.

Palbociclib Plus Aromatase Inhibitor Therapy Provides Real-World Benefit in Older Patients With HR+/HER2– Metastatic Breast Cancer

March 7th 2023

Palbociclib plus an aromatase inhibitor improved real-world data for progression-free survival, overall survival, and time to chemotherapy compared with an aromatase inhibitor alone in patients 75 years and older with hormone receptor–positive, HER2-negative advanced/metastatic breast cancer.

ADCs Advance HR+/HER2– Breast Cancer Treatment Paradigm

March 7th 2023

As more antibody-drug conjugates emerge and investigators foresee fam-trastuzumab deruxtecan-nxki moving forward in lines of treatment for metastatic disease, the treatment landscape of hormone receptor–positive, HER2-negative breast cancer continues to expand and shift.

Updated CheckMate 274 Data Reaffirm Benefit of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma

March 7th 2023

Matthew Galsky, MD, discusses the key long-term findings and the clinical implications of the updated data from the phase 3 CheckMate 274 trial of nivolumab for the adjuvant treatment of patients with urothelial carcinoma.